JP2001520042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001520042A5 JP2001520042A5 JP2000517087A JP2000517087A JP2001520042A5 JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5 JP 2000517087 A JP2000517087 A JP 2000517087A JP 2000517087 A JP2000517087 A JP 2000517087A JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- vitamin
- gla domain
- dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 150000001413 amino acids Chemical group 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- 229930003448 Vitamin K Natural products 0.000 description 22
- 230000001419 dependent effect Effects 0.000 description 22
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 22
- 235000019168 vitamin K Nutrition 0.000 description 22
- 239000011712 vitamin K Substances 0.000 description 22
- 150000003721 vitamin K derivatives Chemical class 0.000 description 22
- 229940046010 vitamin k Drugs 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102400000827 Saposin-D Human genes 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 | 1997-10-23 | ||
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
| PCT/US1998/022152 WO1999020767A1 (en) | 1997-10-23 | 1998-10-20 | Modified vitamin k-dependent polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001520042A JP2001520042A (ja) | 2001-10-30 |
| JP2001520042A5 true JP2001520042A5 (enExample) | 2006-01-05 |
| JP4276379B2 JP4276379B2 (ja) | 2009-06-10 |
Family
ID=25497114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000517087A Expired - Fee Related JP4276379B2 (ja) | 1997-10-23 | 1998-10-20 | 改変型ビタミンｋ依存性ポリペプチド |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6017882A (enExample) |
| EP (2) | EP1090128B1 (enExample) |
| JP (1) | JP4276379B2 (enExample) |
| KR (1) | KR20010031370A (enExample) |
| CN (1) | CN1246462C (enExample) |
| AP (1) | AP2000001811A0 (enExample) |
| AR (2) | AR020048A1 (enExample) |
| AT (1) | ATE390486T1 (enExample) |
| AU (1) | AU749279C (enExample) |
| BR (1) | BR9814611A (enExample) |
| CA (1) | CA2307175C (enExample) |
| DE (1) | DE69839313T2 (enExample) |
| DK (1) | DK1090128T3 (enExample) |
| EA (1) | EA200000449A1 (enExample) |
| ES (2) | ES2496104T3 (enExample) |
| HR (1) | HRP20000234A2 (enExample) |
| HU (1) | HU225993B1 (enExample) |
| ID (1) | ID26330A (enExample) |
| IL (1) | IL135603A0 (enExample) |
| IS (1) | IS5449A (enExample) |
| MY (1) | MY136336A (enExample) |
| NO (1) | NO20002025L (enExample) |
| NZ (1) | NZ504114A (enExample) |
| PL (1) | PL194194B1 (enExample) |
| PT (1) | PT1090128E (enExample) |
| SG (1) | SG105547A1 (enExample) |
| TR (1) | TR200001105T2 (enExample) |
| TW (1) | TW587081B (enExample) |
| WO (1) | WO1999020767A1 (enExample) |
| ZA (1) | ZA989597B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| EP1237917A2 (en) * | 1999-11-19 | 2002-09-11 | Eli Lilly And Company | Protein c derivatives |
| JP2003521919A (ja) | 2000-02-02 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインｃ誘導体 |
| US6630138B2 (en) | 2000-02-11 | 2003-10-07 | Eli Lilly And Company | Protein C derivatives |
| PL206148B1 (pl) | 2000-02-11 | 2010-07-30 | Bayer HealthCare LLCBayer HealthCare LLC | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| CA2455170A1 (en) * | 2000-07-31 | 2002-02-07 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| WO2002070681A1 (en) * | 2001-03-02 | 2002-09-12 | T.A.C. Thrombosis And Coagulation Ab | Protein c variants |
| US20050176083A1 (en) * | 2002-03-01 | 2005-08-11 | Bjorn Dahlback | Recombinant protein c variants |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| RU2004134726A (ru) * | 2002-04-30 | 2005-06-10 | Максиджен Холдингз Лтд. (Ky) | Варианты полипептида фактора vii или viia |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| BRPI0311959B8 (pt) | 2002-06-21 | 2021-05-25 | Novo Nordisk Healthcare Ag | composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| RU2364626C2 (ru) | 2003-03-18 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x |
| CA2519873C (en) | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
| ATE458057T1 (de) * | 2003-06-19 | 2010-03-15 | Bayer Healthcare Llc | Varianten der faktor-vii- oder -viia-gla-domäne |
| ES2381110T3 (es) | 2003-09-09 | 2012-05-23 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| CN1890257A (zh) | 2003-12-01 | 2007-01-03 | 诺和诺德医疗保健公司 | 液体因子ⅶ组合物的病毒过滤 |
| KR20140093711A (ko) | 2003-12-19 | 2014-07-28 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물 |
| EP2368579A1 (en) | 2004-01-21 | 2011-09-28 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| EP2360171A1 (en) | 2004-12-23 | 2011-08-24 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| EP2360170A3 (en) | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine |
| US7696318B2 (en) | 2005-07-13 | 2010-04-13 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
| EP1924689B1 (en) | 2005-09-01 | 2014-08-13 | Novo Nordisk Health Care AG | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第ｖｉｉ因子ポリペプチド |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| JP2010513462A (ja) * | 2006-12-20 | 2010-04-30 | バイエル・ヘルスケア・エルエルシー | 第ＶＩＩおよび第ＶＩＩａ因子組成物 |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| SI2235197T1 (sl) | 2007-12-27 | 2017-10-30 | Baxalta GmbH | Procesi celične kulture |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| PL2440239T3 (pl) | 2009-06-09 | 2018-01-31 | Prolong Pharmaceuticals Llc | Kompozycje hemoglobiny |
| CN102686603B (zh) * | 2009-12-14 | 2014-12-17 | 国立大学法人北海道大学 | 对脂质膜结构体赋予细胞透过能力和/或增强脂质膜结构体的细胞透过能力的肽、以及含有与这些肽结合了的脂质作为构成脂质的具有细胞透过能力或细胞透过能力得到增强的脂质膜结构体 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| WO2014018120A1 (en) | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT87688B (pt) * | 1987-06-12 | 1992-09-30 | Hoechst Japan | Processo para a preparacao de proteina hibrida c |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Ceased
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Ceased
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001520042A5 (enExample) | ||
| AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
| Lwebuga-Mukasa et al. | Molecular forms of acetylcholinesterase from Torpedo californica: their relation to synaptic membranes | |
| Sadler | Thrombomodulin structure and function | |
| Kato et al. | Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme | |
| Ogata et al. | Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain | |
| TW585871B (en) | Improved methods for processing activated protein C | |
| Clark et al. | Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phosoholipase C in mammalian cells | |
| WO2001045746A3 (en) | Methods and compositions for prolonging elimination half-times of bioactive compounds | |
| JP2799316B2 (ja) | 雑種ヒトプロテインｃおよびその遺伝子工学的製法 | |
| CA2102208A1 (en) | Binding domains in notch and delta proteins | |
| JP2002513556A5 (enExample) | ||
| KR20160008521A (ko) | 콜레스테롤 수준을 변경하는 조성물 및 방법 | |
| CA2674879A1 (en) | Improved fix-mutant proteins for hemophilia b treatment | |
| KR910003094A (ko) | 흡혈박쥐속(Vampire bat) 타액 플라스미노겐 활성인자 | |
| CA2563675A1 (en) | Recombinantly modified plasmin | |
| US20240352090A1 (en) | Use of protein sequence capable of binding to substrate in preparation of product for inhibiting fibrin assembly | |
| AU2444795A (en) | A process for separating milk clotting enzymes, and stable rennet compositions | |
| CA2253246A1 (en) | Purified multimerase | |
| Friedman et al. | Vitamin K-dependent carboxylation | |
| CA2002833A1 (en) | Interferon-gamma binding proteins | |
| CA1258242A (en) | Urokinase zymogen and composition containing the same | |
| Noda et al. | Activation of immobilized, biotinylated choleragen A1 protein by a 19-kilodalton guanine nucleotide-binding protein | |
| ATE121456T1 (de) | Klonierung und überexpression von glucose-6- phosphat-dehydrogenase aus leuconostoc dextranicus. | |
| Vatandoost et al. | Effect of propeptide amino acid substitution in γ‐carboxylation, activity and expression of recombinant human coagulation factor IX |